Skip to search
Skip to main content
Catalog
Help
Feedback
Your Account
Library Account
Bookmarks
(
0
)
Search History
Search in
Keyword
Title (keyword)
Author (keyword)
Subject (keyword)
Title starts with
Subject (browse)
Author (browse)
Author (sorted by title)
Call number (browse)
search for
Search
Advanced Search
Bookmarks
(
0
)
Princeton University Library Catalog
Start over
Cite
Send
to
SMS
Email
EndNote
RefWorks
RIS
Printer
Bookmark
Colloid and interface science in pharmaceutical research and development / Hiroyuki Ohshima, Kimiko Makino.
Format
Book
Language
English
Εdition
First edition.
Published/Created
Amsterdam : Elsevier, 2014.
Description
xv, 516 pages : illustrations ; 24 cm
Availability
Copies in the Library
Location
Call Number
Status
Location Service
Notes
Lewis Library - Stacks
QD549 .C65 2014
Browse related items
Request
Details
Subject(s)
Colloids
[Browse]
Surface chemistry
[Browse]
Drug delivery systems
[Browse]
Drug development
[Browse]
Pharmacy
—
Research
[Browse]
Pharmaceutical chemistry
[Browse]
Drugs
—
Design
[Browse]
Editor
Ohshima, Hiroyuki, 1944-
[Browse]
Makino, Kimiko
[Browse]
Bibliographic references
Includes bibliographical references and index.
Contents
Note continued: 13.2. Basic Character of PEG
13.3. Biofouling Resistant Mechanism on PEG Modified Surface Based on the Molecular Structure
13.4. PEGylation
13.4.1. PEGylation for Biomolecules
13.4.2. PEGylation for Solid Substrate
13.5. PEGylated Block Copolymer for Nanostructured Materials and Surfaces
13.6. PEGylated for the Fabrication of High-Performance Metal Nanoparticles
13.6.1. Metal Nanoparticle for Biological System Detection
13.6.2. PEGylation of Metal Nanoparticles for their Bioanalytical Applications
13.6.3. PEGylated Block Copolymer for Nanoreactor
13.6.4. PEGylated Copolymer with Multivalent Anchor to Metal Surface
13.7. Conclusion
References
ch. 14 PEGylated Polymer Micelles for Anticancer Drug Delivery Carrier
14.1. Introduction
14.2. Polymer Micelles as an Anticancer Drug Delivery Carrier
14.3. PEG-b-PVBP Block Copolymer-Based PEGylated Polymer Micelles (DOX@PNP)
14.4. Enhanced Intracellular Drug Delivery of DOX@PNPs in Multidrug-Resistant (MDR) Cancer Cells
14.5. Conclusion
ch. 15 Convective Diffusion of Nanoparticles to Regional Lymph Nodes from the Epithelial Barrier
15.1. Introduction
15.2. Modelling Fluid Flow in Interstitium Around Initial Capillary Initiated by Intrinsic Pump
15.3. Distribution of Fluid Velocity in the Interstitium Between the EB and an Adjacent ILC
15.4. Time of Transport Through Interstitium
15.5. Discussion
15.6. Summary and Conclusions
ch. 16 Highly Fluorinated Colloids in Drug Delivery and Imaging
16.1. Properties of F-Compounds
16.1.1. Fluorous Phase
16.1.2. Encapsulation and Stabilisation
16.1.3. High Oxygen Solubility
16.1.4. Imaging
16.1.5. Toxicity
16.2. Nano-Sized F-Colloids
16.2.1. Controlled Release of Hydrophobic Drugs
16.2.2. Ionic F-Colloids
16.2.3. Paramagnetic Drug Delivery Vehicles
16.2.4. Pulmonary Delivery, Research Tools, and Other Diverse Applications
16.3. Micron-Sized F-Colloids
16.3.1. Microbubbles
16.3.2. Emulsions
16.3.3. Pulmonary Applications
16.3.4. Current F-Colloidal Pharmaceuticals
16.3.5. Conclusion
ch. 17 Cell-Penetrating Peptide Polymer Nanomicelle-Based Cytosol-Sensitive Nucleotide Delivery Systems
17.1. Introduction
17.2. Overview of Cytosol-Sensitive Polymer for Gene Delivery
17.2.1. Disulphide-Linked Cationic Polymer Carriers
17.2.2. Disulphide-Crosslinked Polypeptide
17.3. Cytoplasm-Sensitive Artificial CPP Micelles
17.3.1. Cell-Penetrating Peptides
17.3.2. Artificial CPP Carrier
17.4. Conclusion
Acknowledgements
ch. 18 Cycloamylose-Based Nanocarriers as a Nucleic Acid Delivery System
18.1. Introduction
18.2. Polymer-Based Nucleic Acid Nanocarriers
18.3. Cycloamylose
18.4. Functionalized Cycloamylose for siRNA Delivery
18.5. Functional Cycloamylose for pDNA Delivery
18.6. Cycloamylose Nanogel Gene Delivery: Enhancing Endosomal Escape Using Phospholipase A2
18.7. Conclusion
ch. 19 Colloidal Drug Delivery System for Brain-Targeting Therapy
19.1. Introduction
19.2. Colloidal Drug Delivery System in Pharmaceutical Application
19.2.1. Particle Size
19.2.2. Particle Shape
19.2.3. Surface Charge
19.2.4. Targeting Moiety on Particle Surface
19.3. Colloidal Formulation for Treating Brain Pathology and Disease
19.3.1. Acute Ischaemic Stroke
19.3.2. Brain Tumour
19.3.3. Alzheimer's Disease
19.3.4. Parkinson's Disease
ch. 20 Colloidal Carriers for Noninvasive Delivery of Insulin
20.1. Introduction
20.2. Noninvasive Routes of Insulin Delivery
20.2.1. Oral Route
20.2.2. Buccal and Sublingual Routes
20.2.3. Nasal Route
20.2.4. Pulmonary Route
20.3. Barriers to Noninvasive Insulin Delivery
20.3.1. The Enzymatie Barrier
20.3.2. The Absorption Barrier
20.3.3. Overcoming the Enzymatic Barrier
20.3.4. Overcoming the Absorption Barrier
20.4. Colloidal Carriers for Noninvasive Insulin Delivery
20.4.1. Liposomes
20.4.2. Microparticles
20.4.3. Nanoparticles
20.4.4. Microemulsions
20.4.5. Uptake of Colloidal Carriers
20.5. Market Status of Noninvasive Insulin Delivery System
20.6. Future Scope
ch. 21 Particle Geometry, Charge, and Wettability: The Fate of Nanoparticle-Based Drug Vehicles
21.1. Introduction
21.2. Drug Adsorption
21.2.1. Size and Shape Effects
21.2.2. Drug
particle Interaction
21.3. Transport in the Blood Vessels
21.3.1. The Role of Particle Geometry
21.3.2. Surface Charge and Thermodynamics
21.4. Particle Uptake by Tumour Cells
21.4.1. Role of Particle Size and Shape
21.4.2. Surface Charge and Hydrophobicity
21.5. Particle Release and Toxicity
ch. 22 Lipid Emulsions and Lipid Vesicles Prepared from Various Phospholipids as Drug Carriers
22.1. Introduction
22.2. Particle Size and Entrapment in Liposomes Prepared with Egg Yolk Lecithins and Hydrogenated Egg Yolk Lecithins
22.2.1. Materials and Methods
22.2.2. Results and Discussion
22.3. Properties of Various PCs as Emulsifiers or Dispersing Agents in Nanoparticle Preparations for Drug Carriers
22.3.1. Materials and Methods
22.3.2. Results and Discussion
22.4. Physicochemical Properties of Structured PC in Drug Carrier Lipid Emulsions
22.4.1. Materials and Methods
22.4.2. Results and Discussion
22.5. Conclusion
References.
Machine generated contents note: ch. 1 Interaction of Colloidal Particles
1.1. Introduction
1.2. Potential Distribution Around a Charged Surface: The Poisson--Boltzmann Equation
1.2.1. Hard Particle
1.2.2. Soft Particles
1.3. Electrical Double Layer Interaction Between Two Particles
1.3.1. Linear Superposition Approximation
1.3.2. Derjaguin's Approximation
1.4. van der Waals Interaction Between Two Particles
1.4.1. Two Molecules
1.4.2. A Molecule and a Plate
1.4.3. Two Parallel Plates
1.4.4. Two Spheres
1.4.5. Two Cylinders
1.4.6. Two Particles Immersed in a Medium
1.4.7. Two Parallel Plates Covered with Surface Layers
1.5. DLVO Theory of Colloid Stability
1.5.1. Total Interaction Energy Between Two Spherical Particles
1.5.2. Positions of a Potential Maximum and a Secondary Minimum
1.5.3. The Height of a Potential Maximum and the Depth of a Secondary Minimum
1.5.4. Stability Map
1.6. Conclusion
ch. 2 Colloid and Interface Aspects of Pharmaceutical Science
2.1. General Introduction
2.2. Disperse Systems ~
2.2.1. Thermodynamic Considerations
2.2.2. Kinetic Stability of Disperse Systems and the General Stabilisation Mechanisms
2.3. Surface Activity and Colloidal Properties of Drugs
2.4. Naturally Occurring Micelle Forming Systems
2.5. Biological Implications of the Presence of Surfactants in Pharmaceutical Formulations
2.6. Solubilised Systems
2.7. Liposomes and Vesicles in Pharmacy
2.8. Stabilisation of Liposomes by Incorporation of Block Copolymers
2.9. Nanoparticles, Drug Delivery and Drug Targetting
2.10. The Reticuloendothelial System
2.11. Influence of Particle Characteristics
2.12. Surface-modified Polystyrene Particles as Model Carriers
2.13. Biodegradable Polymeric Carriers
ch. 3 Interracial Properties of Therapeutic Pulmonary Surfactants Studied by Thin Liquid Films
3.1. Introduction
3.2. Thin Liquid Films and Methods for their Experimental Research
3.2.1. Thin Liquid Films: Foam Films, Wetting Films
3.2.2. Microscopic Foam Films and Wetting Films: Methods for their Formation and Study
3.2.3. Micro-Interferometric Method and Pressure Balance Technique
3.3. Black Foam Films
3.3.1. A Model to Study Alveolar Stability and Structure
3.3.2. Method for Lung Maturity Assessment
3.4. Therapeutic Pulmonary Surfactants
3.5. Inhibitory Effect on Therapeutic Pulmonary Surfactants
3.6. Wetting Behaviour of Pulmonary Surfactant Aqueous Solutions
3.6.1. Solid Surfaces with Different Hydrophobicity
3.6.2. Dependence of the Wetting Contact Angles on the Concentration of the Pulmonary Surfactant Aqueous Solution
3.6.3. Thickness of Wetting Films from Pulmonary Surfactant Aqueous Solutions
3.7. Conclusions
ch. 4 Surface Interactions in Propellant Driven Metered Dose Inhaler Product Design
4.1. Introduction
4.2. Surfactant Behaviour in Non-Aqueous Solution
4.2.1. Surfactant Alone
4.2.2. Surfactant-Co-Solvent
4.2.3. Surfactant-Particle Surface
4.2.4. Surfactant-Container Surface
4.2.5. Surfactant-Valve
4.3. Particle Behaviour in Non-Aqueous Solution
4.3.1. Particle Suspension
4.3.2. Particle-Particle Interactions
4.3.3. Particle-Container Wall Interaction
4.4. Aerosol Droplet Formation and Dispersion
4.4.1. Formulation Contribution
4.4.2. Actuator Dimensions
4.4.3. Flash Evaporation from the Metering Valve
4.4.4. Droplet Evaporation and Spray Plume Development
4.5. Formulation Development Strategy
4.5.1. Drug Selection
4.5.2. Micronisation
4.5.3. Design Space
4.5.4. Process Development
4.5.5. Experimental Design
4.5.6. Dissolution (Simple, Reproducible Method)
4.5.7. Mathematical Model
4.6. Conclusion
ch. 5 Particle-Manufacturing Technology-Based Inhalation Therapy for Pulmonary Diseases
5.1. Introduction
5.2. Pulmonary Diseases
5.2.1. Pulmonary Tuberculosis
5.2.2. Lung Cancer
5.2.3. Chronic Obstructive Pulmonary Disease
5.3. Lung Defence System
5.3.1. Structure
5.3.2. Mucus Layer
5.3.3. Pulmonary Surfactant
5.4. Characteristics of Inhalable Particles
5.4.1. Particle Size
5.4.2. Dispersibility
5.5. Manufacturing Technologies for Production of Inhalable Particles
5.5.1. Milling
5.5.2. Spray-Drying
5.5.3. Encapsulation by Lipids
5.5.4. Freeze-Drying
5.6. Clinical Applications of Inhalable Particles
5.6.1. Pulmonary Tuberculosis Therapy
5.6.2. Nanoparticle-Based Lung Cancer Therapy
5.6.3. Inhalation Therapy for COPD
5.7. Summary
ch. 6 QSAR Study for Transdermal Delivery of Drugs and Chemicals
6.1. Introduction
6.2. Viewpoints of the Conventional QSAR
6.3. QSAR Descriptors of Hydrophobicity
6.4. Pharmaceutical Approaches of QSAR
6.5. Thermodynamic Parameters of Dissolution and Melting
ch. 7 Nanoparticles for Transdermal Drug Delivery System (TDDS)
7.1. Introduction
7.2. Nanoparticles for Transdermal Drug Delivery
7.3. Combination of Nanoparticle System and IP
7.4. Improved Nanoparticles for Iontophoretic Transdermal Drug Delivery
7.5. Conclusions
ch. 8 Interfacial and Colloidal Properties of Emulsified Systems: Pharmaceutical and Biological Perspective
8.1. Introduction
8.2. Types of Emulsion
8.3. Colloidal and Interfacial Properties of Emulsified Systems
8.3.1. Interfacial Properties
8.3.2. Electrical Properties
8.4. Mechanism of Emulsion Formation and Stabilisation
8.4.1. Spontaneous Curvature CO
8.5. Pharmaceutical Aspects of Emulsified Systems
8.5.1. Globule Size and Size Distribution
8.5.2. ζ Potential or Surface Charge
8.6. Emulsifying Agents and their Mechanism of Stabilisation
8.7. Behaviour of Emulsions in Biological Milieu
8.8. Oral Administration
8.8.1. Stability of Emulsion During Transit Through GI Tract
8.9. Parenteral Administration
8.9.1. Interaction with Plasma Proteins and Blood Cells
8.9.2. Pharmacokinetics and Tissue Distribution
8.10. New Class of Emulsifying Agents
8.11. Modifications and Recent Advances in Emulsified Systems As a Drug Delivery Vehicle
8.12. Conclusion
ch. 9 Size-Based Characterisation of Nanomaterials by Taylor Dispersion Analysis
9.1. Introduction and Theoretical Aspect
9.1.1. Introduction and Historical Background
9.1.2. TDA: Theoretical Aspect
9.2. Corrections
9.2.1. Corrections Due to Capillary Geometry
9.2.2. Corrections Due to the Mobilisation Pressure Ramp
9.2.3. Corrections Due to the Finite Injected Volume
9.3. Double/Single-Detection Point(s) for TDA
9.4. Polydisperse and Monodisperse Samples: Signal Integration and Average Diffusion Coefficient
9.5. Applications of TDA
ch. 10 Peculiarities of Live Cells' Interaction with Micro- and Nanoparticles
10.1. Introduction
10.2. Experiment
10.2.1. Relationship Between Transmembrane and ζ-Potentials: Biospecific Mechanism of DL Formation
10.2.2. Long-range Interactions of Microparticles with Live Cells
10.2.3. Reversible Interaction of Live Cells with Gold Nanoparticles
10.2.4. Gold Nanoparticles Affect Cell Metabolism and Penetrate Inside Cells
10.3. Theory
10.3.1. Micro-Dielectrophoresis
10.3.2. Micro-Diffusiophoresis
10.3.3. Models Explaining Reversibility of the Interaction of Nanoparticles with Live Cells by Movement of Delocalized ions and Related `Electrosmotic Trap'
10.4. Conclusions
Appendix General Concepts of Live Cell Electrophysiology
ch. 11 Micropatterning of Cell Aggregate in Three Dimension for In Vivo Mimicking Cell Culture
11.1. Introduction
11.2. Cell Patterning Techniques
11.2.1. The Basis of Cellular Patterning; Nonfouling Surface Chemistries
11.2.2. Dry Etching (Plasma Etching)
11.2.3. Cell Assembly for Tissue Engineering
11.2.4. Photolithography
11.2.5. Soft Lithography
11.2.6. Hanging Drop
11.3. Conclusion
ch. 12 Adhesion-Dependent Cell Regulation Via Adhesion Molecule, Integrin Therapeutic application of Integrin Activation-Modulating factors
12.1. Eradication of Acute Myelogenous Leukaemia by Combination Therapy of Anticancer Drug with Antiadhesive Peptide FNIII14
12.1.1. Introduction
12.1.2. FNIII14 Abrogates CAM-DR in AML Cells
12.1.3. Molecular Mechanism of CAM-DR Abrogation by FNIII14
12.1.4. Combination Therapy of Peptide FNIII14 with AraC Abrogated Bone Marrow MRD in AML Model Mouse
12.1.5. Effect of the Combination Therapy on Myelosuppression
12.1.6. Conclusion
12.2. Potentiated and Sustained Activation of VLA-4 and VLA-5 Accelerates Proplatelet-Like Formation
12.2.1. Introduction
12.2.2. Stimulation with PMA of Cells Adhered on Fibronectin Is Effective for PPF
12.2.3. Identification of Fibronectin Receptor Involved in Adhesion-Dependent PPF Induction with PMA
12.2.4. Signalling Pathway for PMA-Induced PPF on Fibronectin Substrate
12.2.5. Effect of Integrin Activation on PMA-Induced PPF on Fibronectin Substrate
12.2.6. Conclusion
12.3. Concluding Remarks
ch. 13 PEGylation for Biocompatible Surface
13.1. Introduction --
Show 305 more Contents items
ISBN
9780444626141 ((cloth))
044462614X ((cloth))
OCLC
885017210
Statement on language in description
Princeton University Library aims to describe library materials in a manner that is respectful to the individuals and communities who create, use, and are represented in the collections we manage.
Read more...
Other views
Staff view
Ask a Question
Suggest a Correction
Report Harmful Language
Supplementary Information